- Home
- GORV vs BNR Comparison
GORV vs BNR Comparison
Compare GORV & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- BNR
- Stock Information
- Founded
- GORV 1976
- BNR 2014
- Country
- GORV United States
- BNR China
- Employees
- GORV N/A
- BNR N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- BNR Medical Specialities
- Sector
- GORV Consumer Discretionary
- BNR Health Care
- Exchange
- GORV Nasdaq
- BNR Nasdaq
- Market Cap
- GORV 26.5M
- BNR 30.9M
- IPO Year
- GORV 2015
- BNR 2020
- Fundamental
- Price
- GORV $0.22
- BNR $2.94
- Analyst Decision
- GORV Hold
- BNR
- Analyst Count
- GORV 2
- BNR 0
- Target Price
- GORV $2.00
- BNR N/A
- AVG Volume (30 Days)
- GORV 156.5K
- BNR 20.3K
- Earning Date
- GORV 05-14-2025
- BNR 05-28-2025
- Dividend Yield
- GORV N/A
- BNR N/A
- EPS Growth
- GORV N/A
- BNR N/A
- EPS
- GORV N/A
- BNR N/A
- Revenue
- GORV $871,562,000.00
- BNR $70,669,261.00
- Revenue This Year
- GORV $15.65
- BNR $136.32
- Revenue Next Year
- GORV $20.54
- BNR N/A
- P/E Ratio
- GORV N/A
- BNR N/A
- Revenue Growth
- GORV N/A
- BNR N/A
- 52 Week Low
- GORV $0.20
- BNR $2.62
- 52 Week High
- GORV $4.00
- BNR $8.99
- Technical
- Relative Strength Index (RSI)
- GORV 32.94
- BNR 24.38
- Support Level
- GORV $0.23
- BNR $2.77
- Resistance Level
- GORV $0.27
- BNR $3.29
- Average True Range (ATR)
- GORV 0.04
- BNR 0.30
- MACD
- GORV 0.01
- BNR 0.01
- Stochastic Oscillator
- GORV 22.16
- BNR 13.82
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.